The Original Hallmarks (2000)

In their landmark 2000 synthesis, Hanahan and Weinberg⁷ proposed that the vast heterogeneity of cancer could be distilled into six essential biological capabilities acquired during multistep tumorigenesis. These included sustained proliferative signaling, whereby cancer cells achieve autonomy from exogenous growth cues through constitutive activation of oncogenic pathways such as RAS–MAPK and PI3K–AKT. Complementing this, tumor cells exhibit evasion of growth suppressors, disabling critical checkpoint regulators including TP53 and RB, thereby uncoupling proliferation from normal tissue constraints. A third hallmark, resistance to apoptosis, reflects the capacity of cancer cells to circumvent programmed cell death through dysregulation of intrinsic and extrinsic apoptotic pathways, often via modulation of BCL-2 family proteins and caspases. In parallel, tumors acquire replicative immortality, typically through activation of telomerase or alternative lengthening of telomeres (ALT), enabling indefinite proliferative potential.

The induction of angiogenesis constitutes another critical adaptation, allowing tumors to secure a sustained supply of oxygen and nutrients through pro-angiogenic factors such as vascular endothelial growth factor (VEGF). Finally, activation of invasion and metastasis enables dissemination beyond the primary tumor site, involving complex processes such as epithelial–mesenchymal transition (EMT), extracellular matrix remodeling, and cytoskeletal reorganization. Collectively, these six hallmarks established a robust framework linking molecular aberrations to phenotypic traits that define malignancy.

The Next Generation (2011)

A decade of subsequent research necessitated expansion of the framework to incorporate emerging insights into cancer metabolism, immune surveillance, and genomic instability. Two additional hallmarks were introduced⁸. The first, reprogramming of energy metabolism, recognizes the metabolic plasticity of cancer cells, exemplified by the Warburg effect, wherein glycolysis is favored even under normoxic conditions. Beyond glycolysis, tumors exhibit adaptive rewiring of lipid, amino acid, and mitochondrial metabolism to sustain biosynthetic and bioenergetic demands.

The second addition, evasion of immune destruction, reflects the ability of tumor cells to avoid recognition and elimination by the host immune system. Mechanisms include downregulation of antigen presentation machinery, secretion of immunosuppressive cytokines, and exploitation of immune checkpoint pathways such as PD-1/PD-L1 and CTLA-4. Importantly, the 2011 update also introduced two enabling characteristics that facilitate the acquisition of hallmark capabilities. Genome instability and mutation generate the genetic diversity necessary for clonal selection and tumor evolution, while tumor-promoting inflammation provides a supportive microenvironment enriched in growth factors, survival signals, and pro-angiogenic mediators. This expanded framework underscored the interplay between intrinsic genetic alterations and extrinsic microenvironmental influences in driving tumor progression.

New Dimensions (2022)

Recent conceptual advances have further refined the hallmarks paradigm by incorporating insights from epigenetics, tumor ecology, and cellular dynamics⁹. A central addition is epigenetic reprogramming, which enables heritable yet reversible modulation of gene expression through mechanisms such as DNA methylation, histone modification, and chromatin remodeling. These processes contribute to tumor heterogeneity, lineage plasticity, and therapeutic resistance without requiring changes in DNA sequence. Another critical dimension is the Tumor Microenvironment (TME), now recognized as an active participant in cancer progression rather than a passive scaffold. The TME comprises a heterogeneous assembly of stromal cells, immune infiltrates, endothelial cells, and extracellular matrix components, all of which engage in bidirectional signaling with tumor cells. This crosstalk shapes key processes including angiogenesis, immune evasion, and metastatic dissemination.

The concept of cellular plasticity has also emerged as a defining feature of malignancy. Cancer cells can dynamically transition between differentiated and stem-like states, as well as between epithelial and mesenchymal phenotypes, enabling adaptation to environmental stress and therapeutic pressure. In parallel, the microbiome has been implicated as a modulator of tumorigenesis, influencing inflammation, immune responses, metabolism, and even the efficacy of anticancer therapies. These additions collectively expand the hallmarks framework into a more integrative model encompassing both genetic and non genetic determinants of cancer behavior.

Emerging Concepts (2025–2026)

The most recent conceptual developments move beyond discrete hallmark categories toward a systems-level paradigm that conceptualizes cancer as a dynamic, evolving ecosystem¹⁰. Within this framework, tumors are understood as complex multicellular communities, characterized by spatial and temporal heterogeneity and governed by intricate networks of intercellular communication. These include paracrine signaling, metabolic coupling, extracellular vesicle exchange, and immune modulation. A key feature of this emerging perspective is the recognition of intercellular interactions as fundamental drivers of tumor behavior. Cooperative and competitive dynamics among cancer subclones, stromal elements, and immune populations contribute to adaptive evolution, therapeutic resistance, and metastatic potential. Moreover, cancer is increasingly viewed as a systemic disease, influenced by host physiology, including endocrine, metabolic, and immune systems, as well as environmental and lifestyle factors.

This paradigm emphasizes the dynamic and non-linear nature of tumor progression, where feedback loops, stochastic events, and ecological pressures shape disease trajectories. Such complexity challenges traditional reductionist approaches and necessitates integrative analytical frameworks capable of capturing multi-scale biological interactions. The progressive evolution of the hallmarks framework, from a set of static cellular capabilities to a dynamic, systems-level model, provides a critical foundation for integrating AI. AI-driven approaches offer unprecedented capacity to decode high-dimensional data, model complex biological networks, and translate hallmark-based concepts into predictive and actionable insights, thereby enabling the realization of next-generation precision oncology.

Types of Artificial Intelligence Relevant to Oncology

The broad field of AI encompasses several computational paradigms, among which machine learning (ML), deep learning (DL), and generative AI have become particularly relevant in cancer research and practice¹⁴. Machine learning refers to a class of algorithms that learn patterns from data and improve performance without explicit rule-based programming. In oncology, supervised, unsupervised, and reinforcement learning approaches have been applied to tasks such as tumor classification, survival prediction, biomarker identification, and treatment response modeling¹⁵. Traditional ML methods, including random forests, support vector machines, gradient boosting, and clustering algorithms, have proven useful for structured biomedical datasets, especially when interpretable outputs are needed¹⁶.

Deep learning, a specialized subset of machine learning, relies on multilayered artificial neural networks capable of automatically learning hierarchical feature representations from complex and unstructured data. Deep learning has shown particular strength in oncology applications involving digital pathology, radiology, histomorphology, and multimodal biomarker analysis¹⁷. Convolutional neural networks, recurrent neural networks, graph neural networks, and transformer-based architectures are increasingly used to analyze images, genomic sequences, longitudinal patient trajectories, and network-level biological interactions¹⁸.

More recently, generative AI has introduced a new dimension to oncology research. These models, including generative adversarial networks, variational autoencoders, and large language models, are capable of generating synthetic data, simulating biological scenarios, assisting hypothesis generation, supporting drug design, and enhancing clinical decision support¹⁹. In cancer research, generative AI holds promise for augmenting limited datasets, modeling tumor evolution, designing novel molecules, and facilitating literature synthesis, although its reliability, interpretability, and ethical implications remain under active evaluation²⁰.

Major Data Sources for Artificial Intelligence in Oncology

The utility of AI in oncology is fundamentally dependent on the diversity, scale, and quality of the data on which it operates. Modern cancer research generates a wide spectrum of data types, each reflecting different layers of tumor biology and patient status²⁰. At the molecular level, genomic data provide information on somatic mutations, copy number alterations, structural rearrangements, and mutational signatures, offering insight into the genetic drivers of tumorigenesis²¹. Transcriptomic data add a dynamic layer by capturing gene expression patterns, alternative splicing events, and regulatory activity, thereby revealing cellular states and pathway activation²². Proteomic data further extend this framework by characterizing protein abundance, post-translational modifications, and signaling dynamics, which are often more proximal to phenotype than genomic alterations alone²³.

Beyond molecular profiling, imaging data represent one of the most powerful domains for AI application in oncology. Radiological imaging, histopathological slides, immunohistochemical staining, and advanced digital pathology platforms generate rich spatial and structural information that can be mined for tumor classification, grading, microenvironment characterization, and treatment response prediction. Increasingly, radiomics and pathomics approaches are being integrated with molecular data to create multidimensional predictive models²⁴. Equally important are clinical data, including demographic characteristics, disease stage, laboratory parameters, treatment regimens, comorbidities, longitudinal outcomes, and electronic health records. These data provide the real-world clinical context necessary for translating AI-derived patterns into patient-centered applications. When integrated across modalities, such datasets enable a more complete and biologically meaningful representation of cancer than any single data source alone²⁵.

Functional Roles of AI in Cancer Research

The primary value of AI in oncology lies in its ability to transform heterogeneous datasets into actionable knowledge. One of its most fundamental roles is pattern recognition, whereby AI can detect subtle, multidimensional relationships that may be inaccessible to traditional statistical approaches. This includes identifying molecular subtypes, recognizing histopathological features, detecting radiological signatures, and uncovering latent associations among biomarkers, pathways, and outcomes¹¹. A second major role is prediction modeling. AI-driven models are increasingly used to estimate diagnosis, prognosis, recurrence risk, metastatic potential, drug sensitivity, and treatment toxicity. These predictive functions are particularly relevant to precision oncology, where individualized therapeutic decisions require accurate, data-informed risk stratification and response forecasting.A third and increasingly important role is systems biology integration¹⁴.

AI provides a framework for integrating these multi-level data into coherent biological models, enabling the study of tumor ecosystems, intercellular communication, metabolic rewiring, immune interactions, and dynamic disease evolution. In this sense, AI is not merely a computational tool but a conceptual bridge between biological complexity and clinical application²⁶. Taken together, AI has become indispensable to contemporary oncology by enabling a transition from fragmented data interpretation to integrated, predictive, and biologically informed cancer analysis. Its growing relevance is especially evident when viewed through the lens of the Hallmarks of Cancer, where the challenge is not simply to describe tumor capabilities, but to decode how these capabilities emerge, interact, and evolve across diverse datasets and clinical contexts⁵.

Sustained Proliferative Signaling

Sustained proliferative signaling is a defining feature of malignancy, driven by constitutive activation of oncogenic pathways such as EGFR, RAS, MYC, and PI3K–AKT. AI-based frameworks, particularly deep learning and network-based machine learning models, have demonstrated remarkable capacity to identify aberrant signaling cascades from multi-omics data. Integrative approaches combining genomic mutations, transcriptomic profiles, and proteomic signatures enable the reconstruction of oncogenic networks with high resolution ³.

Predictive AI models have been employed to infer cell cycle dysregulation, including alterations in cyclins, cyclin-dependent kinases (CDKs), and checkpoint regulators. These models can stratify tumors based on proliferative indices and predict responsiveness to targeted therapies such as CDK inhibitors. Furthermore, AI-driven pathway inference algorithms uncover nonlinear interactions within proliferative signaling networks, providing insights into tumor heterogeneity and clonal evolution³⁹.

Evading Growth Suppressors

The inactivation of tumor suppressor pathways, particularly those governed by TP53, RB1, and PTEN, represents a critical step in tumorigenesis. AI methodologies have significantly enhanced the detection and functional interpretation of tumor suppressor gene alterations, including point mutations, copy number variations, and epigenetic silencing⁴⁰.

Machine learning classifiers trained on large-scale cancer datasets can accurately predict TP53 functional status and downstream pathway disruption, even in the absence of overt genomic alterations. Additionally, AI-driven integrative analyses can identify compensatory pathways that emerge following tumor suppressor loss, offering opportunities for synthetic lethality-based therapeutic strategies. These approaches enable a more nuanced understanding of how tumor cells circumvent growth inhibitory signals⁴¹.

Resisting Cell Death (Apoptosis)

Resistance to programmed cell death is mediated through complex alterations in apoptotic signaling networks, including dysregulation of BCL-2 family proteins, caspases, and mitochondrial pathways. AI-based models have been instrumental in reconstructing these pathways and identifying critical nodes that confer survival advantage ⁴².

Deep learning approaches applied to transcriptomic and proteomic data enable apoptosis pathway modeling, revealing context-specific dependencies across cancer types. Moreover, AI-driven drug response prediction platforms integrate molecular profiles with pharmacogenomic datasets to forecast sensitivity or resistance to pro-apoptotic agents, including BH3 mimetics and chemotherapy. These predictive frameworks are increasingly being incorporated into precision oncology pipelines to optimize therapeutic selection ⁴³.

Replicative Immortality

Replicative immortality, primarily mediated by telomerase activation (TERT) and alternative telomere maintenance mechanisms, is essential for sustained tumor growth. AI approaches have been utilized to analyze telomere length dynamics, TERT promoter mutations, and associated epigenetic modifications across diverse malignancies⁴⁴.

Machine learning models integrating genomic instability metrics, such as mutational burden and chromosomal aberrations, provide insights into the relationship between telomere maintenance and genomic evolution. AI-driven analyses also enable the identification of biomarkers associated with replicative potential and prognosis, offering potential avenues for targeting telomere biology in cancer therapy⁴⁵.

Inducing Angiogenesis

Tumor angiogenesis is orchestrated by a network of pro-angiogenic factors, most notably vascular endothelial growth factor (VEGF), and is critical for tumor expansion and metastasis. AI methodologies have been widely applied to model angiogenic signaling pathways and to quantify vascular characteristics within tumors⁴⁶.

In silico modeling approaches leverage multi-omics data to predict VEGF pathway activation and identify regulatory interactions with hypoxia-inducible factors (HIFs). Concurrently, deep learning applied to medical imaging, particularly radiomics and histopathology, enables non-invasive assessment of tumor vascularization, microvessel density, and perfusion patterns. These imaging-based AI tools have demonstrated utility in predicting response to anti-angiogenic therapies and monitoring treatment efficacy⁴⁷.

Activating Invasion and Metastasis

Metastasis remains the principal cause of cancer-related mortality and involves complex processes such as epithelial–mesenchymal transition (EMT), extracellular matrix remodeling, and cellular motility. AI-driven predictive models have been developed to assess metastatic potential by integrating genomic, transcriptomic, and clinical data⁴⁸.

Machine learning algorithms can identify molecular signatures associated with metastatic dissemination and stratify patients based on risk of recurrence or distant spread. Additionally, AI-based modeling of EMT dynamics captures the continuum of epithelial and mesenchymal states, providing insights into tumor plasticity and therapeutic resistance. Advanced image analysis techniques further enable the detection of invasive phenotypes at the histological level, enhancing early identification of aggressive disease⁴⁹.

Reprogramming Cellular Metabolism

Metabolic reprogramming, including the Warburg effect, is a hallmark of cancer that supports rapid proliferation and adaptation to environmental stress. AI-based systems biology approaches have been pivotal in reconstructing metabolic networks and identifying key regulatory nodes within cancer metabolism⁵⁰.

By integrating metabolomic, transcriptomic, and fluxomic data, AI models can characterize tumor-specific metabolic phenotypes and predict metabolic vulnerabilities. These approaches facilitate the identification of therapeutic targets within glycolysis, glutaminolysis, and lipid metabolism pathways. Moreover, AI-driven modeling of metabolic plasticity provides insights into how tumors adapt to nutrient deprivation and therapeutic pressure⁵¹.

Avoiding Immune Destruction

The ability of tumors to evade immune surveillance is central to cancer progression and has become a major focus of therapeutic intervention. AI has significantly advanced the understanding of tumor–immune interactions and the prediction of immunotherapy responses ⁵².

Machine learning models integrating genomic features such as tumor mutational burden, neoantigen load, and immune gene signatures enable accurate prediction of response to immune checkpoint inhibitors. AI-driven analysis of single-cell sequencing data further elucidates the heterogeneity of immune cell populations within the tumor microenvironment. Additionally, deep learning applied to histopathological images can quantify immune infiltration and spatial organization, providing clinically relevant biomarkers for immunotherapy stratification ⁵³.

Collectively, these advances demonstrate that AI serves as a powerful integrative platform for decoding the biological complexity underlying the hallmarks of cancer. By linking molecular alterations to functional phenotypes and clinical outcomes, AI not only enhances mechanistic understanding but also enables the translation of hallmark-based concepts into predictive, actionable strategies for next-generation precision oncology.

Tumor Microenvironment

The Tumor Microenvironment (TME) comprising malignant cells, cancer-associated fibroblasts (CAFs), endothelial cells, immune infiltrates, and extracellular matrix (ECM) is a central determinant of tumor progression and therapeutic response. AI has enabled high-resolution decoding of TME architecture through multimodal data integration⁵³.

Deep learning applied to digital pathology (whole-slide images) and radiomics can quantify immune infiltration (e.g., TIL density), stromal composition, vascular patterns, and spatial organization. Convolutional neural networks (CNNs) and transformer-based models extract features that correlate with immune phenotypes (inflamed vs. “cold” tumors) and predict outcomes to checkpoint blockade⁵⁴. In parallel, single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics analyzed with machine learning (e.g., graph neural networks, variational autoencoders) reconstruct cell–cell communication networks, including ligand–receptor interactions and cytokine signaling axes⁵⁵. Network-based AI models further integrate angiogenic signaling (VEGF/HIF), ECM remodeling, and immune checkpoints, enabling prediction of therapeutic vulnerabilities within the TME. Importantly, spatially aware AI captures heterogeneity across tumor regions, revealing niches of immune exclusion or hypoxia that drive resistance⁵⁶.

Phenotypic Plasticity

Phenotypic plasticity, the capacity of cancer cells to transition between states (e.g., epithelial–mesenchymal transition [EMT], stem-like states, drug-tolerant persisters) underlies metastasis and therapy resistance. AI enables longitudinal and cross-sectional modeling of these dynamic state transitions⁵⁷.

Unsupervised learning (e.g., non-negative matrix factorization, diffusion maps, pseudotime inference) applied to single-cell data reconstructs cellular trajectories and lineage relationships, capturing EMT continua rather than binary states. Deep generative models (e.g., variational autoencoders, GANs) simulate state transitions under perturbations, enabling in silico exploration of plasticity-driven resistance⁵⁸. Clonal evolution is further resolved using AI methods that integrate somatic mutation profiles, copy number alterations, and phylogenetic inference, delineating subclonal architectures and their temporal dynamics. Coupled with longitudinal liquid biopsy data, AI supports real-time tracking of tumor evolution, anticipating resistance before clinical relapse⁵⁹.

Epigenetic Reprogramming

Epigenetic reprogramming, including DNA methylation, histone modification, chromatin accessibility, and 3D genome organization, drives tumor heterogeneity independent of DNA sequence changes. AI has transformed epigenomic analysis by enabling high-dimensional pattern recognition and integrative modeling⁶⁰.

Machine learning frameworks analyze whole-genome bisulfite sequencing and array-based methylation data to identify cancer-specific methylation signatures for early detection and classification. Deep learning models applied to ATAC-seq and ChIP-seq infer regulatory element activity and transcription factor binding landscapes, linking epigenetic states to gene expression programs⁶¹. Importantly, AI integrates epigenomic layers with transcriptomics to define regulatory circuits governing plasticity and resistance (e.g., enhancer reprogramming, super-enhancers). Emerging 3D genome models (Hi-C–based) analyzed with graph-based AI capture chromatin topology and long-range interactions, revealing structural determinants of oncogene activation. These approaches enable the identification of epigenetic vulnerabilities and rational targeting with epigenetic therapies⁶².

Microbiome–Cancer Interactions

The microbiome has emerged as a critical modulator of tumor biology, influencing inflammation, metabolism, immune tone, and response to therapy. AI facilitates the integration of metagenomic, metabolomic, and host data to decipher microbiome–cancer interactions⁶³.

Machine learning models applied to 16S rRNA and shotgun metagenomics identify microbial signatures associated with cancer risk, progression, and treatment response (notably to immunotherapy). Network-based approaches map microbe–host–immune interactions, linking microbial metabolites (e.g., short-chain fatty acids, bile acids) to signaling pathways in tumor and immune cells⁶⁴. Multi-view learning frameworks integrate microbiome profiles with host genomics and immune phenotypes, improving prediction of therapeutic outcomes. These models also support causal inference strategies to distinguish correlation from functional impact, guiding microbiome-targeted interventions (e.g., probiotics, fecal microbiota transplantation)⁶⁵.

Integrative Multi-omics Fusion

Modern AI architectures (e.g., multi-modal deep learning, autoencoders, transformers) integrate heterogeneous datasets to construct composite molecular profiles. These approaches reconcile differences in scale, noise, and dimensionality, enabling robust patient stratification, subtype discovery, and biomarker identification. Feature attribution methods (e.g., SHAP, integrated gradients) enhance interpretability by identifying key drivers across omics layers⁷². Key strategies and clinical applications of AI-based multi-omics integration across cancer research are summarized in Table 3

Network-based Cancer Modeling

AI-driven network biology reconstructs gene regulatory networks, protein–protein interactions, and signaling pathways. Graph-based models (e.g., graph neural networks) encode biological relationships and propagate information across networks to identify hub nodes and driver modules. These frameworks capture non-linear dependencies and context-specific rewiring of pathways, facilitating discovery of synthetic lethal interactions and combinatorial targets⁸⁷.   

Systems Oncology and Predictive Modeling

In systems oncology, AI integrates multi-omics with clinical and imaging data to build predictive models of disease trajectory and treatment response. Digital twin frameworks simulate patient-specific tumor behavior under different therapeutic scenarios, enabling in silico trials and adaptive treatment optimization⁸⁸. Crucially, AI supports end-to-end pipelines from data ingestion to decision support: (i) data harmonization and quality control, (ii) representation learning, (iii) predictive modeling, and (iv) clinical translation. When coupled with prospective validation and rigorous benchmarking, these systems move the field toward actionable precision oncology, where hallmark-driven biology is quantitatively mapped to individualized care⁸⁹.

By operationalizing the new dimensions of cancer biology, TME complexity, cellular plasticity, epigenetic regulation, and microbiome interactions, and integrating them through multi-omics AI frameworks, modern oncology is transitioning from descriptive models to predictive, systems-level medicine. These advances lay the foundation for next-generation precision oncology, where AI-enabled insights directly inform patient-specific diagnostics and therapeutics⁹⁰.

Clinical Applications of Artificial Intelligence in Precision Oncology

The translation of AI from discovery science to clinical practice is reshaping oncology by enabling data-driven, individualized decision-making across the cancer care continuum. By integrating multimodal data, spanning imaging, pathology, genomics, and longitudinal clinical records—AI systems provide quantitative, reproducible, and scalable tools that complement clinical expertise⁹¹. Below, we delineate the principal clinical domains in which AI is exerting transformative impact. The major clinical applications of AI across the oncology continuum, together with typical data types and translational outputs, are summarized in Table 4.

Collectively, the applications summarized in Table 6 demonstrate that AI is increasingly positioned across the full continuum of precision oncology, from early detection and histopathologic classification to prognosis, treatment selection, longitudinal monitoring, and clinical-trial optimization. Rather than serving as a single diagnostic adjunct, AI is emerging as an integrative clinical layer that links imaging, pathology, molecular profiling, and real-world patient data into more individualized and scalable cancer care pathways. However, the magnitude of its clinical impact will ultimately depend on prospective validation, interoperability with routine workflows, and responsible implementation in diverse patient populations.

Diagnosis

AI has substantially advanced cancer detection and classification through the analysis of radiological and histopathological data. In radiomics, machine learning and deep learning models extract high-dimensional quantitative features from imaging modalities such as CT, MRI, and PET, capturing tumor morphology, texture, heterogeneity, and spatial context beyond human visual perception. These features enable early detection, tumor characterization, and differentiation between benign and malignant lesions, often with performance comparable to or exceeding expert radiologists¹⁰¹.

In digital pathology, convolutional neural networks (CNNs) and vision transformers applied to whole-slide images (WSIs) can identify malignant cells, grade tumors, and classify histological subtypes with high accuracy. AI models also quantify tumor-infiltrating lymphocytes, stromal content, mitotic activity, and other microenvironmental features, linking morphology to underlying molecular states. Increasingly, integrated radiopathomic approaches combine imaging and histology with molecular data to generate comprehensive diagnostic profiles, thereby enhancing diagnostic precision and reducing inter-observer variability¹⁰².

Prognosis

Accurate prediction of clinical outcomes is central to precision oncology. AI-driven prognostic models leverage multi-omics data, imaging features, and clinical variables to estimate survival, recurrence risk, and disease progression with improved discriminatory power over traditional staging systems¹⁰².

Machine learning algorithms, including ensemble methods and deep neural networks, are trained on large, annotated cohorts to identify prognostic signatures that capture tumor aggressiveness and patient-specific risk. Integration of time-to-event modeling (e.g., deep survival networks) enables dynamic prediction of outcomes over the disease course¹⁰³. Additionally, AI models can incorporate longitudinal data, such as serial imaging or liquid biopsy measurements, to provide real-time risk assessment and monitor treatment response. Importantly, explainable AI techniques facilitate the interpretation of prognostic models by identifying key features driving predictions, thereby enhancing clinical trust and enabling biological insight into determinants of disease outcome¹⁰⁴.

Therapeutic Decision-making

AI is increasingly being deployed to support treatment selection and personalization, addressing the complexity of matching patients to optimal therapies in the context of tumor heterogeneity. By integrating genomic alterations, transcriptomic profiles, and clinical data, AI systems can predict drug sensitivity and resistance, guiding the selection of targeted therapies, chemotherapy regimens, and immunotherapies¹⁰⁵.

Decision-support platforms utilize knowledge graphs, network-based inference, and machine learning classifiers to map patient-specific molecular profiles to actionable therapeutic options. In immuno-oncology, AI models incorporating tumor mutational burden, neoantigen landscape, and immune signatures predict response to immune checkpoint inhibitors, thereby refining patient selection¹⁰⁶. Furthermore, AI enables adaptive treatment strategies, where therapeutic decisions are continuously updated based on real-time data, including imaging and circulating tumor DNA. Such approaches move beyond static treatment protocols toward dynamic, learning healthcare systems, in which each patient’s data informs ongoing optimization of care¹⁰⁷.

Drug Discovery and Development

AI is revolutionizing the drug discovery pipeline by accelerating target identification, compound design, and preclinical validation. In target discovery, machine learning models analyze multi-omics datasets to identify driver genes, signaling pathways, and synthetic lethal interactions that represent potential therapeutic targets¹⁰⁸.

In AI-guided drug design, deep learning models, including generative adversarial networks (GANs) and reinforcement learning frameworks, can generate novel chemical structures with optimized pharmacokinetic and pharmacodynamic properties. Structure-based AI approaches predict protein–ligand interactions, enabling rapid screening of candidate compounds and reducing reliance on costly experimental assays¹⁰⁹. 

AI is also applied to drug repurposing, identifying existing compounds with potential efficacy in new cancer indications by analyzing molecular similarity and pathway overlap. During clinical development, AI enhances trial design through patient stratification, biomarker identification, and prediction of adverse events, thereby improving trial efficiency and success rates ¹⁰⁹. Major applications of AI across the oncology drug-development pipeline, from target discovery to trial optimization, are summarized in Table 5.

Collectively, these applications show that AI is no longer confined to isolated prediction tasks but is increasingly embedded across the full oncology drug-development continuum. By integrating molecular profiling, structural biology, pharmacology, and clinical data, AI can improve target prioritization, accelerate candidate optimization, refine biomarker-linked therapy selection, and support more adaptive and efficient clinical development ¹²¹.

Across diagnosis, prognosis, therapeutic decision-making, and drug discovery, AI is redefining the clinical landscape of oncology. By transforming heterogeneous biomedical data into actionable knowledge, AI bridges the gap between molecular complexity and clinical application. As these technologies mature and integrate with routine clinical workflows, they hold the promise of delivering truly personalized, data-driven cancer care, thereby advancing the realization of next-generation precision oncology.

Challenges and Limitations

Despite the transformative promise of AI in oncology, its translation into routine clinical practice remains constrained by substantial methodological, technical, ethical, and regulatory challenges. These limitations are not merely operational obstacles but fundamental issues that shape the reliability, generalizability, and clinical legitimacy of AI-enabled precision oncology. A critical appraisal of these challenges is therefore essential if AI is to move beyond proof-of-concept studies toward robust, equitable, and clinically trustworthy implementation. The major translational barriers facing AI in oncology, together with practical mitigation strategies, are summarized in Table 4.

Although AI has demonstrated considerable promise across the oncology continuum, meaningful clinical translation will depend on solving challenges related to representativeness, interpretability, validation, interoperability, and governance. In this context, the future success of AI-based oncology will rely as much on rigorous implementation science and ethical stewardship as on algorithmic innovation.

Data Bias, Heterogeneity, and Generalizability

One of the most significant limitations of AI in oncology arises from the nature of the data on which models are trained. Cancer datasets are inherently heterogeneous, reflecting differences in patient demographics, tumor biology, sequencing platforms, imaging protocols, clinical workflows, and annotation standards. Such heterogeneity may enrich biological diversity, but it also introduces substantial technical variability that can confound model training and reduce reproducibility across institutions¹⁴⁶. A related concern is data bias, which can occur at multiple levels. Many publicly available training datasets disproportionately represent specific populations, often from high-resource centers and predominantly Western cohorts, leading to underrepresentation of ethnic, geographic, and socioeconomic diversity¹⁴⁷. As a result, AI models trained on these datasets may perform well internally yet fail when applied to broader or underrepresented populations, thereby amplifying existing disparities in cancer care. Bias may also arise from imbalanced class distributions, such as overrepresentation of common tumor types, stages, or treatment responses, which can distort model calibration and impair detection of rare but clinically important phenotypes¹⁴⁸.

In addition, multimodal oncology datasets frequently contain missing values, inconsistent follow-up intervals, variable sample quality, and batch effects, all of which complicate integrative modeling. Although imputation methods and normalization frameworks can mitigate some of these issues, they do not fully eliminate the risk of spurious associations. Consequently, the challenge is not simply to accumulate larger datasets, but to develop high-quality, harmonized, and representative datasets that support clinically generalizable AI systems¹⁴⁹.

Lack of Interpretability and the “Black-box” Problem

A major barrier to clinical trust in AI is the limited interpretability of many high-performing models, particularly deep learning architectures. While such models can achieve impressive predictive accuracy, their internal decision-making processes are often opaque, giving rise to the well-known “black-box” problem. In oncology, where decisions may directly affect diagnosis, treatment selection, and survival outcomes, this lack of transparency poses a substantial challenge¹⁵⁰. Clinicians are unlikely to rely on AI recommendations if the rationale behind a prediction cannot be clearly explained, especially when those predictions contradict established clinical judgment or guidelines. Similarly, regulatory bodies and ethics committees may be hesitant to approve AI-driven tools whose outputs cannot be meaningfully interrogated. This issue is particularly acute in settings such as histopathology, radiomics, and multi-omics integration, where AI models may identify predictive patterns that are statistically robust but biologically non-intuitive¹⁵¹.

The growing field of explainable AI (XAI) seeks to address this limitation by developing methods that highlight influential features, assign importance scores, or visualize regions of interest contributing to a given prediction. However, many XAI approaches remain approximate rather than truly mechanistic, and the distinction between explanation and post hoc rationalization remains a matter of active debate. For AI to gain broader acceptance in oncology, future systems must balance predictive power with interpretability, biological plausibility, and clinical transparency¹⁵².

Ethical, Legal, and Social Concerns

The deployment of AI in precision oncology also raises substantial ethical and societal concerns. Chief among these are issues related to privacy, informed consent, data ownership, algorithmic fairness, and accountability. Multi-omics datasets, digital pathology images, and longitudinal clinical records are deeply personal and often identifiable, making secure storage, sharing, and governance of such data a matter of critical importance¹⁵². Ethical concerns also extend to the risk of algorithmic discrimination. If AI systems are trained on non-representative datasets or encode historical inequities embedded in healthcare systems, they may generate biased predictions that systematically disadvantage certain patient groups. In oncology, this could manifest as misclassification of disease risk, inappropriate treatment prioritization, or unequal access to precision therapies¹⁵³.

Questions of responsibility and liability are equally important. When an AI-driven recommendation contributes to an adverse clinical outcome, it is often unclear who is responsible: the software developer, the institution, the clinician, or the regulatory framework that authorised its deployment. Such ambiguity complicates integration into real-world clinical settings and underscores the need for robust ethical oversight and governance structures¹⁵⁴. Moreover, the increasing use of generative AI and automated decision-support systems raises concerns about overreliance on technology, erosion of clinician autonomy, and potential dehumanization of care. AI should therefore be positioned not as a replacement for clinical expertise, but as an augmentative tool that supports, rather than supplants, physician judgment¹⁵⁵.

Barriers to Clinical Validation and Implementation

Perhaps the most important translational challenge is the persistent gap between algorithm development and clinical validation. A large proportion of AI studies in oncology remain retrospective, single-center, and performed under idealized conditions, with limited assessment of external validity. Models that perform well in curated research datasets often degrade substantially in real-world clinical environments, where data are noisier, workflows are less standardized, and patient populations are more heterogeneous¹⁵⁶. Prospective validation, multicenter benchmarking, and randomized clinical studies of AI-assisted decision-making remain relatively scarce. Without such evidence, it is difficult to determine whether AI tools improve meaningful endpoints such as diagnostic accuracy, survival, cost-effectiveness, or quality of care. In addition, integration into clinical workflows requires interoperability with hospital information systems, pathology and radiology platforms, and molecular diagnostics pipelines—technical hurdles that are often underestimated⁸⁵. Regulatory approval presents another major barrier. Unlike static medical devices, many AI systems are adaptive and may evolve as new data are incorporated. This creates challenges for conventional regulatory models, which are not well suited to continuously learning systems. Standardization of performance metrics, reporting guidelines, and post-deployment monitoring is therefore essential ¹⁵⁷.

Finally, implementation depends not only on technical validity but also on clinical usability, workforce training, and institutional readiness. Even the most accurate AI model will have limited impact if clinicians lack confidence in its use, if workflows are disrupted, or if health systems lack the infrastructure to support it. Taken together, these challenges underscore that the future of AI in oncology will depend not only on algorithmic sophistication but also on data quality, interpretability, fairness, ethical governance, and rigorous clinical validation. The path toward AI-enabled precision oncology is therefore not merely a computational challenge, but a multidisciplinary endeavor requiring close collaboration among oncologists, pathologists, bioinformaticians, data scientists, ethicists, regulators, and patients. Addressing these limitations systematically will be essential to ensure that AI evolves into a clinically reliable, equitable, and genuinely transformative force in cancer medicine.

Data Availability Statement

No new data were generated or analyzed in this review article.

Funding

The authors declare that no funding was received for this work.

Ethics Approval and Consent to Participate

Not applicable.

Conflict of Interest

The authors declare no conflict of interest.

Use of Generative AI

Generative AI tools were used only for language improvement and proofreading. The authors reviewed and approved the final content and take full responsibility for the manuscript.